3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
9
Phase NA
7
Phase 3
6
Phase EARLY_PHASE1
1
Phase 2/3
1
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
7
Thoracic
2
Sarcoma
2
Tumor-Agnostic
1
Gynecologic
1
Dermatologic
1
Breast
1
Conditions
Skin Neoplasms
1
Carcinoma, Squamous Cell
1
Interventions
Nivolumab
7
pembrolizumab
5
Ipilimumab
4
Interferon alpha-2
3
relatlimab
2
Etoposide
2
Drug Therapy
2
Dacarbazine
2
Cyclophosphamide
2
sargramostim
1
salicylhydroxamic acid
1
pertuzumab
1
peginterferon alfa-2b
1
peginterferon alfa-2a
1
molgramostim
1
green tea extract polyphenone E
1
fludarabine phosphate
1
entrectinib
1
cyclopropapyrroloindole
1
cobimetinib
1
atezolizumab
1
Whole-Body Irradiation
1
Vincristine
1
Vemurafenib
1
VAP-cyclo protocol
1
Triamcinolone Acetonide
1
Trastuzumab
1
Thiotepa
1
Temozolomide
1
Surgical Procedures, Operative
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Surgical Procedures, Operative
×
Dermatologic
×
Clear all
NCT06295809
2026-05-08
INTerpath-007
Merck Sharp & Dohme LLC
Phase 2/3
Terminated
46 enrolled